木瓜直播

A full 14-day course of the oral postpartum depression pill zuranolone (Zurzuvae), approved in August, will be . (Reuters)

Evidence from 118 clinical trials supported the use of oral naltrexone 50 mg per day and acamprosate as . (JAMA)

The VA is considering using psychedelics to treat . (CBS News Pittsburgh)

An analysis of in Maryland showed several misleading representations of treatment safety and efficacy for multiple mental health conditions. (JAMA Network Open)

In other news, ketamine is becoming a despite few studies demonstrating its efficacy. (AP)

Walmart plans to roll out for customers with autism and ADHD, featuring dimmed lights and less noise. (New York Post)

In its Annual Report to Congress, the U.S. Preventive Services Task Force named as areas requiring urgent research.

Mental disorders, particularly substance use disorders, were linked with a . (eClinicalMedicine)

Inside the controversy of , for which patients are seeking assisted suicide instead of recovery. (Washington Post)

A long-acting injectable formulation of risperidone among patients with schizophrenia in the phase III RISE trial. (Lancet Psychiatry)

The FDA gave 510(k) clearance to the for the treatment of chronic insomnia, Neurovalens announced.

Comment